Amgen Inc.

Common Stock · USD · NASDAQ

AMGNT212

Price

$336.54

-0.72%

Cap

—

Earnings

—

30d Trend

+0.0%

0R0T

Loading chart data...

0 days · % change from startPowered by Brain47

VolatilityModerate

26% annualised over 90 days

BRAIN47 SIGNAL

STRONG

Risk Level43

Quality63

Momentum62

Technical52

Fundamentals56

Raw weighted: 58×Macro 0.99 (−1%)=57

RISK

43/100

90d Volatility

26.1%Moderate

ATR %

2.0%Normal

Max Drawdown (1Y)

-15.8%Normal

QUALITY

63/100

ROE (avg)

100.0%*Excellent

Piotroski F-Score

7/9Strong

Debt/Equity

6.31High leverage

Margin Stability

CV 9.3%Stable

Accruals

-2.5%Cash earnings

Interest Coverage

5.4xAdequate

MOMENTUM

62/100

12-1M Momentum

+19.1%Strong uptrend

6-1M Momentum

-1.5%Flat

1M Return

-0.0%Stable

Relative Strength

+1.2% vs sectorIn-line

TECHNICAL

52/100

RSI (14)

48.3Neutral

Price vs SMA200

+3.6%Bullish trend

MACD

+1.34Bullish momentum

Bollinger Band

59%Mid-range

SMA Cross

Death CrossDeath Cross

Trend Quality (KER)

0.001Noisy/choppy

FUNDAMENTALS

56/100

EV/EBIT

13.8Cheap

P/FCF

19.8Fair

P/S

4.3Fair

PEG

2.29Overpriced growth

Shareholder Yield

3.2%Moderate

Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%

Running historical backtest...

BRAIN47 HORIZON ANALYSIS

<3 months49

3-12 months50

1-5+ years ★61

Long-term compounder with 3.2% yield

BRAIN47'S ASSESSMENT

I rate Amgen Inc. at 57/100 — a STRONG reading on the Brain47 Signal. The strongest factor is quality at 63/100. I classify this as a income position with the strongest thesis on a long-term horizon.

PAST PERFORMANCE

1 MONTH

-0.0%

3 MONTHS

-12.3%

12 MONTHS

+19.1%

Trailing returns — past performance, not a projection.

DETAILED ANALYSIS

Long-term compounder with 3.2% yield. Quality (63) and Momentum (62) are the primary strengths. Historical volatility is moderate at 26%. I classify this as an income position — the 3.2% yield combined with the dividend profile makes it suitable for income generation.

incomeScore: 57/100

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.